Compare DNOW & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DNOW | VERA |
|---|---|---|
| Founded | 1862 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 3.0B |
| IPO Year | 2014 | 2021 |
| Metric | DNOW | VERA |
|---|---|---|
| Price | $14.23 | $37.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $16.67 | ★ $81.30 |
| AVG Volume (30 Days) | ★ 3.0M | 2.5M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,648,000,000.00 | N/A |
| Revenue This Year | $69.47 | N/A |
| Revenue Next Year | $8.01 | $472.48 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 25.68 | N/A |
| 52 Week Low | $10.94 | $19.07 |
| 52 Week High | $17.26 | $56.05 |
| Indicator | DNOW | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 66.95 | 42.34 |
| Support Level | $13.73 | $32.48 |
| Resistance Level | $14.31 | $38.59 |
| Average True Range (ATR) | 0.36 | 2.75 |
| MACD | 0.14 | -0.78 |
| Stochastic Oscillator | 98.08 | 11.67 |
Dnow Inc is a provider of energy and industrial solutions and a distributor of pipe, valves, and fittings (PVF) and pumps, as well as fabrication, assembly, and testing of process and production equipment. It provides a broad mix of products required to build and maintain essential infrastructure and operating equipment across upstream, midstream, gas utilities, downstream, energy transition, and industrial markets, along with value-added supply chain solutions and technical product expertise supported by digital offerings through its DigitalNOW and MRCGO e-commerce platforms. The company operates mainly under the DNOW and MRC brands and has three reportable segments: the United States, which generates the majority of revenue, Canada, and International.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.